BDTX

I am downgrading Black Diamond Therapeutics from Strong Buy to 'Buy' due to slower-than-expected phase 3 initiation for silevertinib in 1st-line non-classical EGFRm NSCLC. BDTX's silevertinib demonstrated a 60% ORR and 86% CNS ORR in phase 2, outperforming current SOC therapies for CNS involvement in this patient subset. Key catalysts in Q4 2026 include updated phase 2 data and crucial FDA feedback on advancing silevertinib to a pivotal phase 3 trial.

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D.

Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.